ANZICS CTG Endorsed Study


PREVENTion with SGLT-2 inhibition of Acute Kidney Injury in intensive care

Study Description

PREVENTS-AKI is a Prospective, multi-centre, parallel group, double blinded, phase III randomised controlled trial to determine whether treatment with a SGLT2 inhibitor, dapagliflozin, compared to placebo decreases the incidence of a composite end point of severe AKI or death in high-risk patients in intensive care units. This study will enrol 3000 patients in 45 – 50 sites globally.

Participants will be patients expected to be treated in the Intensive Care Unit (ICU) for three days or more. Patients will be randomly assigned to receive either dapagliflozin 10 mg or placebo daily while in ICU for up to 30 days.

Management Committee

Martin Gallagher (Chair), Rinaldo Bellomo, Sarah Coggan, Simon Finfer, Naomi Hammond, Sradha Kotwal, Sharon Micallef, Amanda Wang, Elizabeth Yarad, Paul Young

Administering Institution

The George Institute for Global Health

Sample Size

3000 patients


The George Institute for Global Health


CTG 2223-02, NCT05468203


Martin Gallagher (email)

Sharon Micallef (email)